| 发明名称 |
USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING WEAK PATIENTS |
| 摘要 |
The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism. |
| 申请公布号 |
US2014017243(A1) |
申请公布日期 |
2014.01.16 |
| 申请号 |
US201313930070 |
申请日期 |
2013.06.28 |
| 申请人 |
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES |
发明人 |
BOUREL DOMINIQUE;JORIEUX SYLVIE;ROMEUF CHRISTOPHE DE;KLEIN PHILIPPE;GAUCHER CHRISTINE;BIHOREAU NICOLAS;NONY EMMANUEL |
| 分类号 |
C07K16/18;A61P31/00;A61P35/00;C07K16/34 |
主分类号 |
C07K16/18 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
|
| 地址 |
|
